GKM Gesellschaft fuer Therapieforschung mbH
GKM Gesellschaft fuer Therapieforschung mbH is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin deficiency. The Sunshine Study
Sponsor Grifols S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Prospective, randomized, non-treatment controlled, investigator-blinded, multicenter study on the prophylaxis of early childhood symptoms of atopic dermatitis in high-risk children by continuous continuous application of a moisturizing barrier-stabilizing skin cream
Sponsor INFECTOPHARM Arzneimittel und Consilium GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants – a multicentre randomised placebo-controlled clinical trial
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Tretinoin Gel (10 mg/g + 0.25 mg/g) (Test) vs. Acnatac(R) 10 mg/g + 0.25 mg/g Gel (Reference) vs. Vehicle in patients with papulopustular acne
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients undergoing chemotherapy to prevent chemotherapy-induced polyneuropathy (CIPN), to reduce symptoms typical of CIPN and to improve the quality of life of patients with CIPN
Sponsor Wala-Heilmittel GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Ointment (Test) vs. Advantan® 0.1% Ointment (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Cream (Test) vs. Advantan(R) 0.1% Cream (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Ivermectin 10 mg/g Cream (Test) vs. Soolantra® 10 mg/g Cream (Reference) vs. Vehicle in patients with papulopustular rosacea
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
Sponsor Novartis Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for GKM Gesellschaft fuer Therapieforschung mbH?
The 2026-10-09 snapshot links GKM Gesellschaft fuer Therapieforschung mbH to 14 distinct CTIS trials. Recorded services include Data management, Statistical analysis, Clinical monitoring, Electronic data capture, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for GKM Gesellschaft fuer Therapieforschung mbH?
The most frequently recorded therapeutic areas are Dermatology, Neurology, Allergy, Cardiology. Recorded phases include Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to GKM Gesellschaft fuer Therapieforschung mbH conducted?
The linked trials record locations in 12 countries, including Germany, Netherlands, Austria, Denmark, France. These are trial locations, not confirmed office locations or countries where GKM Gesellschaft fuer Therapieforschung mbH delivered services.
What can this page tell me about GKM Gesellschaft fuer Therapieforschung mbH's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under GKM Gesellschaft fuer Therapieforschung mbH. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- GKM Gesellschaft fuer Therapieforschung mbH